Philadelphia, PA (PRWEB) January 09, 2014
The drug safety resource DrugRisk.com has added new information to the site for patients and families of those who have taken the antipsychotic drug Risperdal. According to court documents, plaintiffs alleging the drug caused abnormal breast growth have asked a judge to unseal data from Risperdal clinical studies.
The request claims the Risperdal safety information is of high public importance, court documents show. The formal case is known as In re: Risperdal Litigation; Case No. 100300296, (Philadelphia Court of Common Pleas, Pennsylvania.)
DrugRisk is a consumer resource center giving those who take popular prescription drugs the latest recalls, safety alerts, research and litigation news. Patients can avoid dangerous drugs, see if others are experiencing similar side effects and decide if they need legal advice.
The drug Risperdal was approved by the FDA to treat schizophrenia, bipolar disorder and autism in adults and adolescents. However, Johnson & Johnson recently pled guilty to promoting it for unapproved uses, such as treating ADHD in children, and paid fines of $2.2 billion*.
DrugRisk has added studies linking the drug to gynecomastia, or abnormal breast growth that can be accompanied by milk production**. A recent study also found antipsychotic drugs like Abilify, Risperdal, Seroquel and Zyprexa may triple the risk of type-2 diabetes in children***.
Parents have already filed lawsuits alleging Risperdal caused abnormal breast growth in children, leading Johnson & Johnson to pay settlements****.
Anyone affected by abnormal breast growth or diabetes after taking Risperdal is urged to visit DrugRisk.com or speak with a lawyer about their legal options. Due to the specialized nature of these cases, DrugRisk only recommends lawyers who have already handled Risperdal lawsuits.
Visit http://www.DrugRisk.com today for more information on the research, side effects and litigation news related to Risperdal and other antipsychotic drugs, or to speak with a lawyer.
*Reuters, 11/4/13; reuters.com/article/2013/11/04/us-jnj-settlement-idUSBRE9A30MM20131104
**Cedars-Sinai Division of Endocrinology, Sept. 2012; ncbi.nlm.nih.gov/pubmed/22862307
***Vanderbilt University Medical Center, 8/22/13; news.vanderbilt.edu/2013/08/antipsychotic-drug-use-in-children-for-moodbehavior-disorders-increases-type-2-diabetes-risk/
****Bloomberg, 9/10/12; bloomberg.com/news/2012-09-10/j-j-settles-risperdal-lawsuit-on-opening-day-of-trial.html; Banks v. Janssen Pharmaceuticals, Philadelphia Court of Common Pleas, January Term 2010, No. 00618